CRISPR Therapeutics AG ($CRSP) Stock Forecast: Down 5.3% Today

What is CRISPR Therapeutics AG?

CRISPR Therapeutics AG (CRSP) is a biotechnology company specializing in gene-based medicines utilizing CRISPR technology. The market sentiment was bearish today.

Why is CRISPR Therapeutics AG going down?

CRSP stock is down 5.3% on Jan 8, 2025 15:53

• Key factors contributing to the bearish movement in CRSP stock include:
• Closing at $41.92, reflecting a -1.2% decrease from the prior trading session.
• Negative market sentiment influencing the stock more than the overall market.
• Potential profit-taking by investors following a recent price surge.
• Uncertainty surrounding regulatory approvals for CRISPR-based therapies impacting investor confidence.

CRSP Price Chart

CRSP Technical Analysis

CRSP News

CRISPR Therapeutics AG ( CRSP ) Registers a Bigger Fall Than the Market: Important Facts to Note

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $41.92, moving -1.2% from the previous trading session.

https://www.zacks.com/stock/news/2393327/crispr-therapeutics-ag-crsp-registers-a-bigger-fall-than-the-market-important-facts-to-note

Trending Today

Cardano ($ADA) Crypto Forecast: Up 6.9% Today

XRP ($XRP) Crypto Forecast: Up 10.7% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.2% Today

Gala ($GALA) Crypto Forecast: Up 7.0% Today

Movement ($MOVE) Crypto Forecast: Down 5.0% Today

Ondo ($ONDO) Crypto Forecast: Down 5.1% Today

Chainlink ($LINK) Crypto Forecast: Up 6.7% Today

Memecoin ($MEME) Crypto Forecast: Up 5.1% Today

Horizen ($ZEN) Crypto Forecast: Up 16.2% Today

Litecoin ($LTC) Crypto Forecast: Up 5.1% Today

CRISPR Therapeutics AG Price History

13.08.2024 - CRSP Stock was up 5.4%

• The bullish movement in CRSP today can be attributed to:
• CRISPR Therapeutics AG settling at $45.51, representing a +1.42% change from its previous close, indicating positive investor sentiment.
• The ongoing advancements and developments in CRISPR gene-editing technology, driving optimism about the company's future prospects.
• Increased investor confidence in the biotech sector as a whole, leading to a surge in demand for CRSP shares.

03.11.2024 - CRSP Stock was down 5.1%

• Analysts project a potential upside of 58.3% for CRSP.
• Earnings estimate revisions show a positive trend, hinting at potential future stock growth.
• Despite optimistic analyst outlook, CRSP's stock witnessed a bearish movement today, signaling a discrepancy between predictions and market performance.

06.00.2025 - CRSP Stock was up 4.4%

• CRSP stock demonstrated a robust bullish trend, rising by +1.84% despite overall market conditions.
• The upsurge in CRSP stock could be linked to favorable developments in the company's CRISPR technology.
• Investors may be hopeful about CRSP's future possibilities, prompting heightened buying interest.
• CRSP's steady performance amidst market fluctuations may suggest high investor trust in the company's innovative gene-based therapies approach.

11.09.2024 - CRSP Stock was up 3.4%

• CRSP stock experienced a bullish movement likely due to positive developments in the gene-editing field and potential breakthroughs in CRISPR technology.
• The decision to sell Moderna stock might have redirected investor focus towards CRISPR-based companies like CRISPR Therapeutics, contributing to the bullish trend.
• The market movement could also be influenced by increasing investor confidence in CRSP's pipeline of gene therapies and potential for future growth in the biotech sector.
• Overall, the shift in portfolio and positive industry outlook may have fueled optimism around CRSP, leading to its strong bullish performance today.

28.09.2024 - CRSP Stock was up 1.6%

• CRISPR Therapeutics AG (CRSP) displayed a bullish movement, diverging from the general market direction.
• Investors were likely encouraged by the anticipated Q3 earnings, especially the sales performance of its gene therapy Casgevy.
• Despite recent fluctuations, CRSP's favorable trajectory could be linked to growing investor confidence in its pioneering gene-based treatments.
• The market's positive reception of CRSP's potential for expansion may have eclipsed broader market patterns, contributing to its upward momentum.

20.08.2024 - CRSP Stock was down 5.3%

• CRSP stock slid more than the broader market, indicating specific company-related factors contributing to the decline.
• The slight decrease in stock price could be due to profit-taking by investors after a recent uptrend or concerns about the company's future growth prospects.
• Market fluctuations and overall sentiment may have also played a role in the stock's bearish movement.
• Investors should closely monitor any upcoming company announcements or industry developments that could impact CRSP's stock performance in the near future.

08.00.2025 - CRSP Stock was down 5.3%

• Key factors contributing to the bearish movement in CRSP stock include:
• Closing at $41.92, reflecting a -1.2% decrease from the prior trading session.
• Negative market sentiment influencing the stock more than the overall market.
• Potential profit-taking by investors following a recent price surge.
• Uncertainty surrounding regulatory approvals for CRISPR-based therapies impacting investor confidence.

23.09.2024 - CRSP Stock was down 5.1%

• The downward movement in CRISPR Therapeutics AG (CRSP) may be due to investors taking profits following a recent upturn.
• The potential decrease in CRISPR Therapeutics AG (CRSP) could have been influenced by a major investment firm reducing its stakes in other companies, causing a broader negative market sentiment.
• Despite optimistic forecasts by financial analysts for CRISPR Therapeutics AG (CRSP), current market conditions and profit-taking behaviors likely outweighed the positive outlook, leading to the bearish movement observed today.

11.10.2024 - CRSP Stock was up 6.2%

• Analysts are optimistic about CRISPR Therapeutics, with a mean price target suggesting a significant upside potential of 62.8% in the stock.
• Despite mixed third-quarter results, including a narrower loss than expected and sales missing estimates, the progress in the commercial launch of Casgevy, the first CRISPR-based gene therapy, is a positive indicator for the company's future growth prospects.
• The bullish movement in CRSP today could be attributed to the overall positive sentiment from analysts regarding the company's potential and the advancements in its groundbreaking gene-editing technology.

05.10.2024 - CRSP Stock was down 5.6%

• The strong bearish movement in CRSP today could be attributed to profit-taking by investors after the stock recently surpassed both the 20-day and 50-day moving averages.
• Some investors who closely follow technical analysis may have seen these moving average milestones as potential signals to sell, leading to a temporary downturn in the stock price.
• Despite the bearish movement, the long-term outlook for CRSP remains positive, given its innovative technologies and promising pipeline of gene-based therapies.

07.07.2024 - CRSP Stock was down 5.4%

• Following the Q2 2024 earnings release, CRSP stock showed a downward trend after surpassing EPS expectations but falling short of revenue forecasts by a significant amount.
• Despite being an established company with high growth potential, the lower-than-expected revenue results likely impacted investor confidence.
• The divergence between EPS and revenue performance could signify operational hurdles or slower revenue generation, prompting a sell-off of CRSP stock.
• Investors who were drawn in by the excitement surrounding gene-editing may have swiftly responded to the revenue shortfall, underscoring the volatility of biotech stocks and the significance of financial fundamentals in influencing stock prices.

15.07.2024 - CRSP Stock was up 5.0%

• CRISPR Therapeutics (CRSP) experienced a strong bullish movement today.
• The bullish trend could be attributed to the overall positive sentiment in the biotech industry, with a focus on gene editing stocks.
• The market is optimistic about CRISPR Therapeutics' potential to transform medicine and address genetic disorders.
• The company's recent regulatory approvals and advancements in gene-editing technology likely contributed to investor confidence and drove the stock price higher.